Research News
View articles by month and year
-
Taxotere Combo Improves Survival
The combination of Taxotere (chemical name: docetaxel) and Cytoxan (chemical name: cyclophosphamide) offers better survival and fewer and less severe side effects than the combination of Adriamycin (chemical name: doxorubicin) and Cytoxan for treating breast cancer.
-
Some Young Women Don’t Benefit from Chemotherapy
Chemotherapy has more benefits for hormone-receptor-negative cancers in younger women, compared to hormone-receptor-positive cancers in younger women.
-
Ixempra Approved to Treat Advanced-Stage Breast Cancer
Ixempra (chemical name: ixabepilone) has been approved by the U.S. Food and Drug Administration to treat advanced breast cancers after other chemotherapy medicines have stopped working.
-
African American Women Less Likely to Get Chemo
Research has shown that breast cancer in African American women is genetically different compared to breast cancer in white women. It's usually more aggressive and diagnosed at an earlier age and at a ...
-
Exercise Boosts Self-Esteem During Chemo
Exercise can boost self-esteem, fitness, and treatment completion rates for women getting chemotherapy.
-
Some Women Don’t Benefit from Adding Taxol to Chemo Regimen
An early breast cancer's HER2 status affects the benefits offered by Taxol.
-
Chemo Raises Leukemia Risk Slightly in Older Women
Women who receive chemotherapy have a small increase in risk for a type of leukemia later in life.
-
New Chemo Medicines Treat Metastatic Disease
Average survival times for women diagnosed with metastatic breast cancer are increasing because of new medications.
-
Bonefos Doesn’t Up Survival Rate
Treatment with clodronate does not improve survival in women with early or advanced breast cancer, according to an analysis of published studies.
-
Ixabepilone Gets Faster Review
Ixabepilone, a new chemotherapy medication for advanced breast cancer, has been given priority review by the U.S. Food and Drug Administration.
